| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 17 | 2025 | 377 | 2.180 |
Why?
|
| Erythroid Precursor Cells | 18 | 2013 | 33 | 1.800 |
Why?
|
| Erythroblasts | 13 | 2019 | 27 | 1.680 |
Why?
|
| Hematopoietic Stem Cells | 13 | 2019 | 325 | 1.190 |
Why?
|
| Multiple Myeloma | 7 | 2019 | 353 | 1.190 |
Why?
|
| Erythropoietin | 14 | 2012 | 91 | 1.140 |
Why?
|
| GTPase-Activating Proteins | 3 | 2019 | 68 | 1.110 |
Why?
|
| Erythropoiesis | 15 | 2025 | 53 | 1.080 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2022 | 684 | 1.080 |
Why?
|
| Hematopoiesis | 9 | 2022 | 182 | 0.920 |
Why?
|
| Cord Blood Stem Cell Transplantation | 6 | 2016 | 91 | 0.820 |
Why?
|
| DNA-Binding Proteins | 7 | 2022 | 1267 | 0.810 |
Why?
|
| Signal Transduction | 16 | 2019 | 3581 | 0.770 |
Why?
|
| Transplantation Conditioning | 13 | 2017 | 383 | 0.750 |
Why?
|
| Histones | 4 | 2020 | 362 | 0.740 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2022 | 824 | 0.730 |
Why?
|
| Erythrocytes | 8 | 2013 | 252 | 0.720 |
Why?
|
| Gene Expression Regulation | 11 | 2021 | 2059 | 0.690 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 555 | 0.660 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2017 | 942 | 0.590 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 50 | 0.590 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 59 | 0.580 |
Why?
|
| Stem Cell Factor | 6 | 2012 | 19 | 0.580 |
Why?
|
| Folate Receptor 2 | 1 | 2018 | 1 | 0.560 |
Why?
|
| Transcriptional Activation | 2 | 2019 | 303 | 0.560 |
Why?
|
| Folate Receptor 1 | 1 | 2018 | 4 | 0.560 |
Why?
|
| Phosphorylation | 11 | 2019 | 1156 | 0.560 |
Why?
|
| Apoptosis | 16 | 2017 | 1756 | 0.550 |
Why?
|
| Cell Differentiation | 20 | 2019 | 1662 | 0.550 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 2385 | 0.540 |
Why?
|
| Dioxygenases | 5 | 2022 | 82 | 0.540 |
Why?
|
| Plasma Cells | 2 | 2018 | 88 | 0.540 |
Why?
|
| Tretinoin | 1 | 2018 | 131 | 0.530 |
Why?
|
| Megakaryocytes | 4 | 2018 | 38 | 0.490 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2008 | 71 | 0.470 |
Why?
|
| Erythroid Cells | 4 | 2013 | 16 | 0.460 |
Why?
|
| GATA1 Transcription Factor | 4 | 2025 | 19 | 0.450 |
Why?
|
| Cytokines | 1 | 2019 | 871 | 0.440 |
Why?
|
| Cell Nucleus | 5 | 2019 | 618 | 0.420 |
Why?
|
| Humans | 88 | 2025 | 95992 | 0.410 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 6 | 2012 | 67 | 0.400 |
Why?
|
| Nuclear Proteins | 7 | 2016 | 750 | 0.390 |
Why?
|
| Plasmodium falciparum | 2 | 2011 | 55 | 0.380 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2011 | 10 | 0.350 |
Why?
|
| Transcription Factors | 5 | 2013 | 1729 | 0.350 |
Why?
|
| Actins | 4 | 2015 | 472 | 0.350 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 1533 | 0.350 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 217 | 0.340 |
Why?
|
| Natural Killer T-Cells | 1 | 2011 | 46 | 0.340 |
Why?
|
| Trans-Activators | 3 | 2022 | 446 | 0.340 |
Why?
|
| Cell Proliferation | 5 | 2017 | 1753 | 0.330 |
Why?
|
| Reticulocytes | 2 | 2010 | 25 | 0.330 |
Why?
|
| Cells, Cultured | 20 | 2013 | 2928 | 0.310 |
Why?
|
| Phosphoproteins | 2 | 2022 | 263 | 0.310 |
Why?
|
| Zebrafish Proteins | 2 | 2025 | 160 | 0.310 |
Why?
|
| Malaria, Falciparum | 1 | 2009 | 15 | 0.310 |
Why?
|
| Hematopoietic Cell Growth Factors | 3 | 2002 | 11 | 0.300 |
Why?
|
| Multigene Family | 1 | 2009 | 213 | 0.290 |
Why?
|
| Antigens, CD34 | 12 | 2017 | 163 | 0.290 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 1309 | 0.290 |
Why?
|
| Animals | 31 | 2025 | 28901 | 0.280 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2025 | 487 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2010 | 611 | 0.270 |
Why?
|
| Cell Separation | 3 | 2025 | 205 | 0.270 |
Why?
|
| Osteopontin | 1 | 2008 | 48 | 0.270 |
Why?
|
| RNA, Messenger | 10 | 2009 | 2088 | 0.270 |
Why?
|
| Blood Component Removal | 3 | 2020 | 28 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2022 | 463 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2003 | 224 | 0.260 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 2776 | 0.250 |
Why?
|
| Hematologic Neoplasms | 7 | 2016 | 372 | 0.250 |
Why?
|
| Cytoskeleton | 1 | 2008 | 200 | 0.250 |
Why?
|
| RNA Splicing | 2 | 2025 | 159 | 0.250 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 2021 | 28 | 0.240 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 4 | 2016 | 52 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 3 | 2019 | 13 | 0.230 |
Why?
|
| Receptors, Erythropoietin | 5 | 1999 | 14 | 0.220 |
Why?
|
| Forkhead Transcription Factors | 5 | 2016 | 175 | 0.220 |
Why?
|
| Blood Donors | 2 | 2016 | 24 | 0.220 |
Why?
|
| MicroRNAs | 1 | 2009 | 591 | 0.220 |
Why?
|
| Syndecan-1 | 2 | 2018 | 18 | 0.210 |
Why?
|
| Integrin beta1 | 2 | 2018 | 34 | 0.210 |
Why?
|
| Haplotypes | 4 | 2016 | 652 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2013 | 396 | 0.210 |
Why?
|
| Globins | 3 | 2021 | 31 | 0.210 |
Why?
|
| Transplantation, Homologous | 12 | 2016 | 1023 | 0.210 |
Why?
|
| Flow Cytometry | 8 | 2025 | 725 | 0.210 |
Why?
|
| Cell Division | 5 | 2002 | 701 | 0.210 |
Why?
|
| Mice | 21 | 2025 | 12525 | 0.210 |
Why?
|
| Base Sequence | 8 | 2012 | 2341 | 0.200 |
Why?
|
| Caspase 3 | 4 | 2019 | 164 | 0.200 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 547 | 0.200 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2003 | 20 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2012 | 284 | 0.200 |
Why?
|
| Graft vs Host Disease | 8 | 2017 | 368 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 1999 | 46 | 0.190 |
Why?
|
| RNA Splicing Factors | 1 | 2022 | 30 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2013 | 701 | 0.180 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 206 | 0.180 |
Why?
|
| Epigenomics | 2 | 2020 | 109 | 0.180 |
Why?
|
| Cell Line | 10 | 2021 | 2536 | 0.180 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 173 | 0.180 |
Why?
|
| Interferon-alpha | 3 | 2013 | 194 | 0.180 |
Why?
|
| Interferon-beta | 3 | 2013 | 126 | 0.170 |
Why?
|
| Cytoskeletal Proteins | 2 | 2009 | 227 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2016 | 158 | 0.170 |
Why?
|
| Anemia | 3 | 2025 | 136 | 0.170 |
Why?
|
| Potassium Channels | 1 | 2003 | 359 | 0.170 |
Why?
|
| Male | 25 | 2025 | 45792 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2025 | 667 | 0.160 |
Why?
|
| Protein Binding | 5 | 2019 | 1560 | 0.160 |
Why?
|
| Erythrocyte Membrane | 3 | 2010 | 61 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 1347 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2015 | 187 | 0.160 |
Why?
|
| Forkhead Box Protein O3 | 3 | 2008 | 21 | 0.160 |
Why?
|
| Biomarkers | 3 | 2019 | 1931 | 0.160 |
Why?
|
| Leukemia | 3 | 2012 | 305 | 0.160 |
Why?
|
| Models, Biological | 4 | 2019 | 1810 | 0.150 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2019 | 4 | 0.150 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2010 | 52 | 0.150 |
Why?
|
| Bone Marrow | 3 | 2018 | 415 | 0.150 |
Why?
|
| Polycythemia Vera | 1 | 1999 | 22 | 0.150 |
Why?
|
| Unrelated Donors | 2 | 2017 | 47 | 0.150 |
Why?
|
| Fetal Blood | 2 | 2017 | 95 | 0.150 |
Why?
|
| Dynamin III | 1 | 2018 | 1 | 0.150 |
Why?
|
| Dynamin II | 1 | 2018 | 15 | 0.150 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2021 | 247 | 0.140 |
Why?
|
| Female | 24 | 2025 | 49980 | 0.140 |
Why?
|
| Zebrafish | 2 | 2025 | 342 | 0.140 |
Why?
|
| Cell Movement | 2 | 2019 | 816 | 0.140 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 49 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2000 | 116 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 89 | 0.140 |
Why?
|
| Biological Products | 1 | 2021 | 179 | 0.140 |
Why?
|
| Isoenzymes | 4 | 2009 | 278 | 0.140 |
Why?
|
| Oligonucleotides | 1 | 2018 | 92 | 0.140 |
Why?
|
| Gene Expression | 4 | 2020 | 1319 | 0.140 |
Why?
|
| Kinetics | 5 | 2003 | 1561 | 0.140 |
Why?
|
| Graft Survival | 6 | 2016 | 942 | 0.140 |
Why?
|
| Alternative Splicing | 2 | 2009 | 220 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 245 | 0.130 |
Why?
|
| Mice, Knockout | 5 | 2018 | 2160 | 0.130 |
Why?
|
| Thrombopoiesis | 1 | 2017 | 6 | 0.130 |
Why?
|
| DNA Methylation | 4 | 2017 | 702 | 0.130 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2015 | 48 | 0.130 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 3 | 2010 | 14 | 0.130 |
Why?
|
| Leukapheresis | 1 | 2016 | 16 | 0.130 |
Why?
|
| Wnt Proteins | 1 | 2017 | 131 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 897 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2018 | 740 | 0.120 |
Why?
|
| Primary Myelofibrosis | 1 | 2017 | 68 | 0.120 |
Why?
|
| Ferritins | 1 | 2016 | 31 | 0.120 |
Why?
|
| Aged | 18 | 2017 | 20927 | 0.120 |
Why?
|
| Vidarabine | 4 | 2005 | 146 | 0.120 |
Why?
|
| Enzyme Activation | 5 | 2009 | 692 | 0.120 |
Why?
|
| Haploidy | 1 | 2016 | 31 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2016 | 127 | 0.120 |
Why?
|
| Molecular Chaperones | 2 | 2009 | 127 | 0.120 |
Why?
|
| NADPH Dehydrogenase | 1 | 2015 | 11 | 0.120 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2015 | 21 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 594 | 0.120 |
Why?
|
| beta Catenin | 1 | 2017 | 266 | 0.120 |
Why?
|
| Recombinant Proteins | 6 | 2009 | 1006 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2017 | 526 | 0.110 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2015 | 7 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 712 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 548 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 6 | 2017 | 1046 | 0.110 |
Why?
|
| Interleukin-8 | 1 | 2015 | 88 | 0.110 |
Why?
|
| Chromosome Deletion | 2 | 2017 | 223 | 0.110 |
Why?
|
| Survival Analysis | 6 | 2017 | 1541 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 113 | 0.110 |
Why?
|
| Middle Aged | 20 | 2017 | 28299 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 349 | 0.110 |
Why?
|
| Interferon-gamma | 3 | 2002 | 462 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2016 | 228 | 0.110 |
Why?
|
| Transcription, Genetic | 5 | 2009 | 1191 | 0.110 |
Why?
|
| Cytosine | 3 | 2022 | 135 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2012 | 34 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2014 | 63 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 39 | 0.100 |
Why?
|
| Neuropeptides | 1 | 1994 | 116 | 0.100 |
Why?
|
| Tropomodulin | 1 | 2013 | 1 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 342 | 0.100 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2013 | 18 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2015 | 393 | 0.100 |
Why?
|
| CCAAT-Binding Factor | 1 | 2012 | 2 | 0.100 |
Why?
|
| Adult | 18 | 2016 | 28636 | 0.100 |
Why?
|
| gamma-Globins | 1 | 2012 | 5 | 0.100 |
Why?
|
| RNA Precursors | 2 | 2009 | 73 | 0.100 |
Why?
|
| Young Adult | 9 | 2016 | 7034 | 0.100 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2013 | 167 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 46 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 245 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2013 | 358 | 0.090 |
Why?
|
| Molecular Sequence Data | 5 | 2012 | 3040 | 0.090 |
Why?
|
| Repressor Proteins | 2 | 2012 | 447 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 2 | 2009 | 86 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 677 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 2605 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 188 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2012 | 307 | 0.090 |
Why?
|
| Transplantation Chimera | 2 | 2009 | 84 | 0.090 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2002 | 29 | 0.090 |
Why?
|
| Liver | 2 | 2013 | 1231 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2002 | 367 | 0.090 |
Why?
|
| Smad7 Protein | 1 | 2010 | 8 | 0.080 |
Why?
|
| Growth Inhibitors | 2 | 2002 | 41 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 145 | 0.080 |
Why?
|
| Adolescent | 10 | 2016 | 9878 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 80 | 0.080 |
Why?
|
| Age Factors | 3 | 2012 | 1959 | 0.080 |
Why?
|
| Quinolines | 1 | 2010 | 89 | 0.080 |
Why?
|
| DNA | 5 | 2003 | 1329 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 1991 | 297 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 277 | 0.080 |
Why?
|
| Leukocytes | 1 | 2011 | 213 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2016 | 1127 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 341 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2010 | 161 | 0.080 |
Why?
|
| Mutation | 6 | 2022 | 4374 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2 | 1999 | 9 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2009 | 175 | 0.080 |
Why?
|
| Host-Parasite Interactions | 1 | 2009 | 33 | 0.080 |
Why?
|
| CpG Islands | 3 | 2017 | 169 | 0.070 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 20 | 0.070 |
Why?
|
| Proteasome Inhibitors | 1 | 2009 | 54 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2009 | 55 | 0.070 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 72 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2009 | 151 | 0.070 |
Why?
|
| Thiadiazoles | 1 | 2008 | 12 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2003 | 126 | 0.070 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2008 | 44 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 50 | 0.070 |
Why?
|
| Pyrazines | 1 | 2009 | 94 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 54 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2012 | 542 | 0.070 |
Why?
|
| Inflammation | 1 | 2014 | 1063 | 0.070 |
Why?
|
| Leukemia, Myeloid | 2 | 2009 | 240 | 0.070 |
Why?
|
| Integrin alpha4 | 1 | 2008 | 11 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2009 | 265 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2009 | 454 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 40 | 0.070 |
Why?
|
| Binding Sites | 4 | 2013 | 1167 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2009 | 171 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 110 | 0.070 |
Why?
|
| Spectrin | 3 | 2001 | 15 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 281 | 0.060 |
Why?
|
| Health Status | 1 | 2009 | 386 | 0.060 |
Why?
|
| Heme | 2 | 1999 | 64 | 0.060 |
Why?
|
| RNA, Transfer | 1 | 2009 | 173 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2009 | 1275 | 0.060 |
Why?
|
| Transplantation, Haploidentical | 2 | 2017 | 28 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2025 | 564 | 0.060 |
Why?
|
| K562 Cells | 3 | 2012 | 49 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2008 | 176 | 0.060 |
Why?
|
| Heat-Shock Proteins | 2 | 2007 | 183 | 0.060 |
Why?
|
| Genome, Human | 2 | 2013 | 823 | 0.060 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 140 | 0.060 |
Why?
|
| Cell Survival | 3 | 2018 | 1029 | 0.060 |
Why?
|
| Prognosis | 4 | 2016 | 3993 | 0.060 |
Why?
|
| Living Donors | 1 | 2009 | 348 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2022 | 296 | 0.060 |
Why?
|
| Stem Cells | 4 | 2013 | 394 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 1425 | 0.060 |
Why?
|
| Salvage Therapy | 2 | 2004 | 238 | 0.060 |
Why?
|
| Activin Receptors, Type II | 1 | 2025 | 10 | 0.060 |
Why?
|
| Smad2 Protein | 1 | 2025 | 24 | 0.060 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2025 | 26 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 528 | 0.060 |
Why?
|
| Blotting, Northern | 3 | 2001 | 257 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2012 | 1195 | 0.060 |
Why?
|
| Growth Differentiation Factors | 1 | 2025 | 58 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 2004 | 1014 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 1670 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2003 | 303 | 0.050 |
Why?
|
| Receptors, Purinergic | 1 | 2004 | 7 | 0.050 |
Why?
|
| Tetrodotoxin | 1 | 2004 | 51 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2001 | 33 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2004 | 48 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2009 | 416 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2025 | 132 | 0.050 |
Why?
|
| Protein Transport | 3 | 2012 | 439 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 2 | 2005 | 39 | 0.050 |
Why?
|
| Chromatin | 2 | 2019 | 445 | 0.050 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 2003 | 2 | 0.050 |
Why?
|
| MAP Kinase Kinase 6 | 1 | 2003 | 10 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 193 | 0.050 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2003 | 32 | 0.050 |
Why?
|
| Pregnancy | 1 | 2011 | 3239 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2003 | 85 | 0.050 |
Why?
|
| Sodium Channels | 1 | 2004 | 131 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2004 | 246 | 0.050 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2003 | 5 | 0.050 |
Why?
|
| Treatment Outcome | 7 | 2016 | 9228 | 0.050 |
Why?
|
| Caspases | 2 | 2000 | 156 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 98 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 2003 | 70 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2003 | 52 | 0.050 |
Why?
|
| Premedication | 1 | 2003 | 58 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 196 | 0.050 |
Why?
|
| Acute Disease | 3 | 2012 | 859 | 0.050 |
Why?
|
| Friend murine leukemia virus | 2 | 1993 | 5 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 562 | 0.050 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2022 | 7 | 0.050 |
Why?
|
| Acyclovir | 1 | 2003 | 110 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 135 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 542 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2013 | 156 | 0.050 |
Why?
|
| RNA Interference | 2 | 2018 | 385 | 0.050 |
Why?
|
| Remission Induction | 3 | 2011 | 750 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 2 | 2001 | 66 | 0.050 |
Why?
|
| Anemia, Aplastic | 1 | 2002 | 34 | 0.050 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2002 | 89 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2003 | 155 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 263 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2009 | 297 | 0.040 |
Why?
|
| Acetylation | 1 | 2002 | 149 | 0.040 |
Why?
|
| Temperature | 1 | 2003 | 432 | 0.040 |
Why?
|
| Cell Membrane | 2 | 2018 | 687 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2012 | 12 | 0.040 |
Why?
|
| Clathrin | 2 | 2012 | 32 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 206 | 0.040 |
Why?
|
| Interferons | 1 | 2001 | 119 | 0.040 |
Why?
|
| Vacuoles | 2 | 2012 | 48 | 0.040 |
Why?
|
| Time Factors | 5 | 2009 | 5593 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2001 | 134 | 0.040 |
Why?
|
| Histocompatibility | 2 | 2016 | 66 | 0.040 |
Why?
|
| Neoplasms | 1 | 2016 | 3242 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 1 | 2003 | 150 | 0.040 |
Why?
|
| Chromones | 1 | 2000 | 31 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2009 | 479 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2000 | 58 | 0.040 |
Why?
|
| Fetus | 1 | 2021 | 239 | 0.040 |
Why?
|
| Family | 2 | 2012 | 331 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 157 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2000 | 59 | 0.040 |
Why?
|
| Morpholines | 1 | 2000 | 77 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 750 | 0.040 |
Why?
|
| Illinois | 2 | 2012 | 530 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2022 | 308 | 0.040 |
Why?
|
| Phosphotyrosine | 1 | 1999 | 31 | 0.040 |
Why?
|
| Receptors, Interleukin-3 | 1 | 1999 | 3 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 1642 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 376 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 2090 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1999 | 87 | 0.040 |
Why?
|
| Milk Proteins | 1 | 1999 | 24 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 412 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 1017 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 469 | 0.040 |
Why?
|
| Melphalan | 3 | 2005 | 99 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 1999 | 80 | 0.040 |
Why?
|
| Sirolimus | 1 | 2000 | 177 | 0.040 |
Why?
|
| DNA Primers | 3 | 2009 | 548 | 0.040 |
Why?
|
| RNA | 1 | 2003 | 603 | 0.040 |
Why?
|
| Filgrastim | 2 | 2009 | 57 | 0.040 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2018 | 29 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2018 | 88 | 0.030 |
Why?
|
| Protein Kinases | 1 | 1999 | 216 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 215 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 279 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 7224 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 996 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 101 | 0.030 |
Why?
|
| Exons | 2 | 2009 | 454 | 0.030 |
Why?
|
| Alemtuzumab | 2 | 2009 | 90 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 997 | 0.030 |
Why?
|
| Risk Factors | 3 | 2016 | 5992 | 0.030 |
Why?
|
| Recurrence | 2 | 2016 | 1231 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2013 | 516 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 45 | 0.030 |
Why?
|
| Actin Cytoskeleton | 1 | 2018 | 201 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 38 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 113 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 134 | 0.030 |
Why?
|
| Siblings | 2 | 2009 | 109 | 0.030 |
Why?
|
| Chimerism | 1 | 2016 | 38 | 0.030 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2015 | 26 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 217 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2012 | 984 | 0.030 |
Why?
|
| DNA Probes | 2 | 1994 | 76 | 0.030 |
Why?
|
| Thy-1 Antigens | 1 | 1995 | 16 | 0.030 |
Why?
|
| Mitosis | 1 | 2016 | 152 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 2474 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2009 | 279 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 25 | 0.030 |
Why?
|
| Hypoxia | 1 | 2020 | 681 | 0.030 |
Why?
|
| Transplantation, Autologous | 2 | 2008 | 361 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 156 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 69 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1995 | 226 | 0.030 |
Why?
|
| Microfilament Proteins | 2 | 2009 | 213 | 0.030 |
Why?
|
| Ankyrins | 1 | 1994 | 23 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1827 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 978 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 326 | 0.030 |
Why?
|
| Child | 2 | 2022 | 7621 | 0.030 |
Why?
|
| Enzyme Inhibitors | 3 | 2002 | 655 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 207 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 116 | 0.030 |
Why?
|
| Erythrocyte Aging | 1 | 1993 | 1 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1993 | 71 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 1994 | 106 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2013 | 18 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 890 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 340 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 161 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 171 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2013 | 24 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 155 | 0.020 |
Why?
|
| Incidence | 2 | 2011 | 1723 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1994 | 124 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 33 | 0.020 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 12 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 69 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 102 | 0.020 |
Why?
|
| TATA Box | 1 | 2012 | 11 | 0.020 |
Why?
|
| Dactinomycin | 1 | 1992 | 33 | 0.020 |
Why?
|
| GATA2 Transcription Factor | 1 | 2012 | 16 | 0.020 |
Why?
|
| 5-Methylcytosine | 1 | 2013 | 122 | 0.020 |
Why?
|
| Half-Life | 1 | 1992 | 99 | 0.020 |
Why?
|
| Nucleotide Motifs | 1 | 2012 | 49 | 0.020 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 53 | 0.020 |
Why?
|
| Telomerase | 1 | 2012 | 68 | 0.020 |
Why?
|
| Coated Pits, Cell-Membrane | 1 | 2012 | 7 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 102 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 85 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1992 | 193 | 0.020 |
Why?
|
| Methylation | 1 | 2013 | 295 | 0.020 |
Why?
|
| Introns | 1 | 2013 | 304 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2009 | 1021 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 32 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1561 | 0.020 |
Why?
|
| Survival Rate | 2 | 2008 | 1978 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 983 | 0.020 |
Why?
|
| Nocodazole | 1 | 2010 | 18 | 0.020 |
Why?
|
| Monensin | 1 | 2010 | 16 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 429 | 0.020 |
Why?
|
| Diffusion | 1 | 2010 | 95 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 477 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 269 | 0.020 |
Why?
|
| DNA Polymerase II | 1 | 2009 | 10 | 0.020 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2009 | 6 | 0.020 |
Why?
|
| Splicing Factor U2AF | 1 | 2009 | 5 | 0.020 |
Why?
|
| Cytokinesis | 1 | 2010 | 60 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2009 | 70 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 256 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2009 | 37 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 136 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2009 | 54 | 0.020 |
Why?
|
| Endocytosis | 1 | 2010 | 186 | 0.020 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2009 | 5 | 0.020 |
Why?
|
| Calnexin | 1 | 2009 | 4 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 419 | 0.020 |
Why?
|
| Calreticulin | 1 | 2009 | 16 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2012 | 682 | 0.020 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2009 | 16 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2009 | 13 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 2009 | 11 | 0.020 |
Why?
|
| Galactolipids | 1 | 1988 | 2 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 82 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2009 | 29 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2008 | 38 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2009 | 99 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 936 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3483 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2016 | 10307 | 0.020 |
Why?
|
| Pteridines | 1 | 2008 | 4 | 0.020 |
Why?
|
| Acyltransferases | 1 | 1988 | 53 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2009 | 373 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1982 | 0.020 |
Why?
|
| Lentivirus | 1 | 2008 | 44 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1962 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 460 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 207 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 72 | 0.020 |
Why?
|
| Cyanobacteria | 1 | 1988 | 114 | 0.020 |
Why?
|
| Lymphoma | 1 | 2009 | 253 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 127 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2534 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7785 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 930 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2009 | 263 | 0.020 |
Why?
|
| Benzamides | 1 | 2008 | 248 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 398 | 0.020 |
Why?
|
| Genomics | 1 | 2013 | 857 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 305 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2008 | 249 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 296 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2009 | 935 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 3115 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2008 | 386 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 417 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 835 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 314 | 0.010 |
Why?
|
| Ifosfamide | 1 | 2004 | 37 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 648 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 796 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1819 | 0.010 |
Why?
|
| Etoposide | 1 | 2004 | 207 | 0.010 |
Why?
|
| Thiotepa | 1 | 2003 | 32 | 0.010 |
Why?
|
| Proteins | 1 | 2009 | 816 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 197 | 0.010 |
Why?
|
| Viremia | 1 | 2003 | 53 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 905 | 0.010 |
Why?
|
| Autocrine Communication | 1 | 2002 | 21 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 297 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 113 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2001 | 36 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2001 | 58 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 76 | 0.010 |
Why?
|
| Flavonoids | 1 | 2001 | 85 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2001 | 165 | 0.010 |
Why?
|
| Imidazoles | 1 | 2001 | 144 | 0.010 |
Why?
|
| Vanadates | 1 | 2000 | 32 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 22 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2000 | 20 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 35 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 39 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 49 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 65 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 279 | 0.010 |
Why?
|
| Pyridines | 1 | 2001 | 319 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-crk | 1 | 1999 | 6 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 41 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 1741 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 504 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 1999 | 34 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1999 | 67 | 0.010 |
Why?
|
| STAT5 Transcription Factor | 1 | 1999 | 45 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1998 | 55 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1966 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1999 | 301 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 4690 | 0.010 |
Why?
|
| Countercurrent Distribution | 1 | 1995 | 2 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 1995 | 7 | 0.010 |
Why?
|
| Centrifugation | 1 | 1995 | 24 | 0.010 |
Why?
|
| CD56 Antigen | 1 | 1995 | 18 | 0.010 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1995 | 7 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 1995 | 20 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1995 | 67 | 0.010 |
Why?
|
| Phenylalanine | 1 | 1995 | 36 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1995 | 96 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1995 | 129 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 114 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 2575 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1995 | 139 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 6 | 0.010 |
Why?
|
| Hemin | 1 | 1994 | 5 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1995 | 292 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1995 | 819 | 0.010 |
Why?
|
| Acyl Carrier Protein | 1 | 1988 | 8 | 0.000 |
Why?
|
| Dithiothreitol | 1 | 1988 | 25 | 0.000 |
Why?
|
| Coenzyme A | 1 | 1988 | 13 | 0.000 |
Why?
|
| Diglycerides | 1 | 1988 | 23 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1988 | 42 | 0.000 |
Why?
|
| Glycolipids | 1 | 1988 | 30 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 311 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1988 | 329 | 0.000 |
Why?
|